PPIDT00044
Drug Information
| Name | Cetrorelix |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB00050 |
| Type | small molecule |
| Indication | For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Powder | — |
0.25 mg
|
| Injection, powder, for solution; kit | Subcutaneous |
0.25 mg/1mL
|
| Kit | Subcutaneous |
0.25 mg/2mL
|
| Injection, powder, for solution | Subcutaneous |
0.25 mg/ml
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
3 mg
|
| Kit | Subcutaneous |
0.25 mg/1mL
|
| Kit | Subcutaneous |
3 mg/3mL
|
| Powder, for solution | Subcutaneous |
0.25 mg / vial
|
| Powder, for solution | Subcutaneous |
3 mg / vial
|
| Injection, powder, for solution | Subcutaneous |
0.25 mg
|
| Injection | Subcutaneous |
0.25 MG
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
300000 mg
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
0.25 mg
|
| Injection, solution | — |
0.25 MG
|
| Powder | — |
0.25 mg/1vial
|